News | June 12, 2020

Principia Announces Positive Data from its Phase 2 Part B Trial in Pemphigus Clear dose-response combined with decreased daily corticosteroid usage Response rate increased with extended duration of treatment to six months while maintaining a favorable safety profile...

News | January 7, 2020

Principia Announces Expanded Development Program to Broaden BTK Footprint in Immune-Mediated Diseases Company’s lead candidate PRN1008 receives generic name — rilzabrutinib Rilzabrutinib to enter clinical trial in IgG4-Related Disease SOUTH SAN FRANCISCO,...